1
Introduction 26
Copy number variations (CNV) refer to duplications and deletions that lead to gains or 27 losses of large segments of the chromosomes. CNVs are an abundant source of 28 variations 1 and have been associated with diseases, 2 such as HIV acquisition and 29 progression, 3 autism, 4 schizophrenia, 5 and systemic autoimmune diseases. 6, 7 In cancer, 30 somatic CNVs, also referred to as copy number aberrations (CNAs), are prevailing, as 31
shown by the Cancer Genome Atlas 8 and the International Cancer Genome Consortium; 9 32 these CNAs have been associated with cancer progression and metastases. 10, 11 It is, 33 therefore, important to detect CNVs with high sensitivity and specificity. 34
In order to retain statistical power for association testing, CNV profiles across a 35 large population of samples are required. 12 Recent advances in next-generation 36 sequencing enable genome-wide CNV detection in a high-throughput manner. However, 37 biases and artifacts are introduced during the library preparation and sequencing step, 38 making data normalization crucial for accurate CNV profiling. Several algorithms have 39 been developed to remove experimental noise from GC content bias, 13 sequencing 40 depth, 14 mappability, 15 amplification efficiency, 16 and other latent systematic artifacts. 17,18 41
Yet profiling of somatic CNVs in cancer remains challenging, due to the heterogeneous 42 nature of the tumor samples-the observed copy number signals from bulk DNA 43 sequencing (DNA-seq) are averaged and attenuated across multiple genotypically 44 distinct cancer subpopulations. [19] [20] [21] Tumor purity further dampens the CNV signals, and 45 overall tumor ploidy leads to genome-wide gains or losses of chromosomal copies, all of 46 which make statistical estimation and inference less tractable. 19,20 47 Whole genome single-cell DNA-seq (scDNA-seq) enables the characterization of 48 copy number profiles at the cellular level without the cell subpopulation confounding. This 49 circumvents the averaging effects associated with bulk-tissue DNA-seq, increasing 50 resolution while decreasing ambiguity in deconvolving cancer subclones, thus elucidating 51 cancer evolutionary history ( Supplementary Table S1 ). [22] [23] [24] Conventional whole-genome 52 amplification methods for scDNA-seq include degenerate oligonucleotide primed PCR 53 (DOP-PCR), multiple displacement amplification (MDA), and multiple annealing and 54 looping-based amplification cycles (MALBAC). 25 MDA 26 lacks uniformity, yet has a low 55 sequencing error rate, and it is thus better suited for calling point mutations; DOP-PCR 27 56 and MALBAC, 28 on the other hand, have higher uniformity and have been successfully 57 used for calling CNVs; [19] [20] [21] see Supplementary Table S2 on details of the perspective 58 amplification methods. Recently, 10X Genomics released the Single-Cell CNV Solution 59 (https://www.10xgenomics.com/solutions/single-cell-cnv), which automatically uses 60 microfluidic droplets to barcode cells and performs library construction. In the first step, 61 the single cells are encapsulated into hydrogel cell beads and then lysed. This is followed 62 by a second step of amplification and cell bead partitioning with 10X barcoded gel beads. 63
The amplified and barcoded fragments are then pooled and converted to sequencing 64 libraries. This significantly increases throughput and offers great potential for profiling 65
CNVs across a large population of cells. 66
However, scDNA-seq data across all existing platforms and technologies is sparse, 67 noisy, and highly variable, even within a homogeneous cell population. The extremely 68 shallow and highly non-uniform depth of coverage, which is caused by the non-linear 69 amplification and significant dropout events during the library preparation and sequencing 70 step, 25,29 makes detecting CNVs by scDNA-seq challenging. Furthermore, the cancer 71 genomes undergo large chromosome or chromosome-arm level deletions or duplications, 72 as well as changes in cellular ploidy, which lead to recurrent and frequent CNAs that 73 disrupt a large proportion of the genome across multiple samples. 30 Existing methods for 74 scDNA-seq either build an optimized normal/reference set for normalization 31 or adopt a 75 cell-specific normalization procedure for removing systematic biases (due to, e.g., GC 76 content), followed by a post hoc procedure ploidy estimation and adjustment. 32 These 77 methods, which are adapted from those that are developed for bulk DNA-seq data, do not 78 address the challenges and complexities caused by aberrant copy number changes or 79 the complicating factor of tumor ploidy, and they cannot adequately and correctly remove 80 the artifacts, for they make the invalid assumption that all read counts are sampled from 81 diploid regions under the null when estimating the noise terms. The recurrent CNV signals 82 can either be accidentally removed during the normalization step or bias the correction 83
step. 84
To meet the widespread demand for CNV detection with single-cell resolution, we 85 propose a new statistical and computational framework, SCOPE, for Single-cell COPy 86 number Estimation. The distinguishing features of SCOPE include: (i) utilization of cell-87 specific Gini coefficients for quality control and for identification of normal/diploid cells, 88 which are then used as negative control samples in a Poisson latent factor model for read 89 depth normalization; (ii) modeling of GC content bias using an expectation-maximization 90 (EM) algorithm embedded in the Poisson regression models to account for the different 91 copy number states along the genome; and (iii) a cross-sample iterative segmentation 92 procedure to identify breakpoints that are shared across cells with the same genetic 93 background. We evaluate the performance of SCOPE on real scDNA-seq datasets from 94 several cancer genomic studies, as summarized in Supplementary Table S1 . Compared 95 to existing methods, SCOPE is shown to more accurately estimate subclonal copy 96 number aberrations and to have higher correlation with array-based copy number profiles 97 of purified bulk samples from the same breast cancer patient. We further show that the 98 copy number profiles by scDNA-seq are also be well recapitulated, although at low 99 resolution, by whole-exome sequencing (WES) and single-cell RNA-sequencing (scRNA-100 seq). We finally demonstrate SCOPE on the recently released scDNA-seq data that was 101 produced using the 10X Genomics single-cell CNV pipeline, showing that it can reliably 102 recover 1% of the cancer cell spike-ins from a background of normal cells and 103 successfully reconstruct cancer subclonal structure across 10,000 breast cancer cells. 104 
SCOPE

Methods overview 109
An overview of the SCOPE workflow is shown in Figure 1 . SCOPE takes as input the 110 mapped reads from assembled BAM files, 33 which are pre-processed using the same 111 bioinformatic pipeline (see Supplementary Note S1 for details). SCOPE then generates 112 consecutive bins along the genome and computes the cell-by-bin read depth matrix, as 113 well as the mappability and GC content for each bin. For data normalization, SCOPE 114 adopts a Poisson latent factor model with an embedded EM algorithm to capture both 115 cell-and bin-specific systemic biases and artifacts, as well as GC content bias. SCOPE 116 also incorporates a cross-sample segmentation procedure, enabling shared breakpoints 117 across cells from the same cancer subclone. It then outputs integer-valued copy numbers, 118 allowing direct ploidy estimation without the need for post hoc adjustment. 119
In the following sections, we start with an overview of the sample-specific data 120 normalization and segmentation procedure by Ginkgo 32 and SCNV 31 and the cross-121
sample Poisson latent factor model by CODEX 16 and CODEX2. 18 We then discuss the 122 limitations of the existing models and the reason that existing methods cannot adequately 123 capture the biases and artifacts, explaining why careful statistical modeling with further 124 adaptations is warranted for detecting CNVs by scDNA-seq data. Finally, we describe the 125 model for SCOPE, leaving algorithmic details to the supplements. 126 127
Review of existing methods 128
Several methods have been developed for CNV detection by scDNA-seq, including 129
Ginkgo 32 and SCNV. 31 To compute depth of coverage, both methods aggregate read-130 depth information into variable-length bins. To generate boundaries for the bins, in silico 131 generated reads at every position of the genome are mapped back to the genome, and 132 the bin sizes are chosen such that each bin has the same number of uniquely mapped 133 reads. This step ensures that the bins have approximately the same number of mapped 134 reads on average. To correct for GC content bias, both Ginkgo 32 and SCNV 31 perform 135 normalization within each individual cell separately. Ginkgo 32 employs a locally weighted 136 linear regression (LOWESS curve) to fit the relationship between GC content and log-137 normalized bin counts; 32 similarly, SCNV adjusts for GC content with LOWESS 138 regression. 31 Both methods assume that all reads are from the diploid regions, and both 139 control for the GC biases by modeling the unimodal relationship between GC content and 140 log-scaled read counts. This ignores the multiplicative effects contributed by the different 141 sequential copy-number states in each single cell. 142
In addition, because depth of coverage within each cell is normalized against its 143 own coverage baseline, each cell has a normalized value with mean zero and thus 144 completely masks the cellular ploidy. To solve this issue, both Ginkgo and SCNV adopt 145 a post hoc ploidy estimation procedure and further scale the normalized results by the 146 estimated ploidy to reflect the true copy numbers. In more details, they estimate the ploidy 147 by minimizing a cost function that measures the difference between the scaled copy 148 number. However, the copy numbers and the ploidy, which is the genome-wide average 150 of the copy numbers, are interrelated-the normalized copy number depends on the true 151 underlying ploidy, and the two-step approach estimates ploidy based on the normalization 152 results. This leads to a chicken-and-egg problem that is cyclic. 153
In summary, in existing methods, the recurrent CNV signals, as well as the 154 complicating factor such as ploidy, can either be accidentally removed during the 155 normalization step, which needs a second-step recovery, or bias the correction for known 156 biases, such as those due to different GC content. For illustration, Figure 2 shows fitting 157 of GC content bias in two ways: (i) assuming all bins are from the null region and fitting a 158 non-parametric function using read depths across all bins, a method that, to our best 159 knowledge, is adopted by all existing methods; and (ii) adopting an EM algorithm with the 160 missing data being the carrier status for each bin, which is a simplified implementation of segmentation. Both of these methods lack the ability to construct CNV profiles by 179 adopts a cross-sample segmentation procedure that simultaneously estimates 181 changepoints that are shared across cells. This is extremely important in the single-cell 182 settings, where multiple cells from the same subclone share the same genetic 183 background and thus the same breakpoints for CNVs. The lower panels in Figure 2 show 184 the cross-sample segmentation results by SCOPE across three cells, where the predicted 185 ploidy by SCOPE is in concordance with that from single-cell flow sorting. 186
187
SCOPE model for data normalization 188
The extremely low depth of sequencing coverage, the nonlinear cell-specific biases due 189 to amplification and sequencing, as well as other low-rank systemic artifacts that cannot 190 be directly measured or quantified, 36 make the sample-specific bias correction procedure 191 inadequate to successfully and unbiasedly capture all noise terms. Cross-sample 192 normalization, on the other hand, relies on multiple samples processed in the same 193 experiment run, and it borrows information both across regions and across samples to 194 estimate the bias terms. This normalization strategy based on matrix factorization has 195 been applied in the bulk setting for different types of omics data 16,18,37,38 to adjust for GC 196 content bias and other latent artifacts. Furthermore, RUV 37 and CODEX2 18 extensively 197 utilize negative control genes and negative control samples to estimate latent factors. For 198 CNV detection, it has been shown that this increases CNV signal-to-noise ratio and 199 achieves high sensitivity for both rare and common variants. The experience we have 200 gained over a decade of next-generation sequencing data analysis collectively as a 201 community motivates many of the ingredients of our new proposed approach for single-202 cell DNA sequencing. 203 SCOPE is based on a Poisson latent factor model 16,18 for count-based read depth 204 normalization but is completely standalone and specifically adapted for the single-cell 205 setting. Furthermore, to estimate CNVs by bulk DNA-seq across samples and to estimate 206
CNVs by scDNA-seq across cells from the same sample are two different problems -in 207 cancer genomics, the former profiles inter-tumor heterogeneity across patients, while the 208 latter profiles intra-tumor heterogeneity looking at single cells within a patient. The key 209 innovation in SCOPE is the way it integrates both null and non-null regions, in a genome-210 wide fashion, for unbiased estimation of both GC content bias and latent factors for cell-211 and position-specific background correction. 212
Specifically, let = ( )* ; = 1, … ; = 1, … 3 be the raw read count matrix, where 213 )* is the read depth for cell ∈ {1, … , } and bin ∈ {1, … , }. SCOPE assumes that 214 )* ∼ Poisson= )* ?, 215 )* = * ) * ( ) ) )* exp FG )I ℎ *I K ILM N. 216 * is a cell-specific library size factor, which can be globally estimated as the median 217 ratio; 39 ) reflects bias due to bin-specific length, capture and amplification efficiency; 218 * ( ) ) is a sample-specific non-parametric function to capture the GC content bias, )I 219 and ℎ *I (1 ≤ ≤ ) are the th bin-and cell-specific latent factors with orthogonality 220 restraints, which force identifiability; and )* specifies the sequential multiplicative 221 increment due to different copy number states. )* is discretized to fit the single-cell 222 setting with integer-valued copy numbers and to ensure identifiability with * different 223 copy number states within a specific cell For parameter estimation, SCOPE adopts an iterative procedure, where EM is 238 embedded as one step to estimate the GC content bias. For EM initializations, SCOPE 239 utilizes ploidy estimates from a first-pass normalization run to ensure fast convergence 240 and to avoid local optima (Supplementary Figure S2 ). See algorithmic details in the 241 Supplementary Note S2. For estimation of , the number of latent factors, SCOPE, by its 242 default, adopts BIC as a model selection metric. Notably, we demonstrate that with the 243 EM algorithm to account for the local genomic contexts and the use of normal cells to 244 estimate bin-specific noise terms, the procedure outlined above by SCOPE is robust to 245 the different choice of K (see under Discussion for more details). 246
The histograms in Figure 3 show the normalization results for a breast cancer 247 dataset across four methods -CODEX2, Ginkgo, Ginkgo with post hoc adjustment by the 248 estimated ploidy, and SCOPE. We observe that neither CODEX2 nor Ginkgo attains 249 unbiased separation of different copy number states. To solve this issue and to obtain 250 integer-valued copy number estimates, Ginkgo 32 adopts a post hoc ploidy estimation 251 procedure, followed by a cell-specific scaling step; these ensure that the average copy 252 number across all bins matches the estimated ploidy, an adjustment that allows Ginkgo 253 to achieve better separation of CNV signals. SCOPE, on the other hand, retains precise 254 segregation of CNV signals from the biological and technical noise, and distributions of 255 the normalized -score are centered at the expected integer copy-number values. 256
Furthermore, SCOPE offers direct ploidy estimates, based on the estimated copy 257 numbers along the genome, completely off the shelf. 258 259
Identification of negative control cells 260
In most, if not all, single-cell cancer genomics studies, diploid cells are inevitably picked 261 up for sequencing from adjacent normal tissues and they can thus serve as normal 262 controls for read depth normalization. However, not all platforms/experiments allow or 263 adopt flow-sorting based techniques before scDNA-seq, and thus cell ploidy and case-264 control labeling are not always readily available. To solve this issue, SCOPE opts to in cell, we calculate its Gini coefficient as two times the area between the diagonal line and 267 the Lorenz curve, shown in Supplementary Figure S3 . Equivalently, the Gini coefficient 268 of cell can be calculated as 269
which serves as a robust and scale-independent measurement of coverage uniformity. 271
As such, cell-specific Gini coefficients can be used as good proxies for identifying cell 272 outliers, which have extreme coverage distribution due to failed library preparation, and 273
for indexing normal cells out of the entire cell population. the carrier probability is not known a priori, it is estimated empirically by 308
The optimal number of changepoints is determined via max ¢ mBIC( ). For more details 310 on the interpretation of the terms in mBIC, see Zhang and Siegmund. 41 311
After segmentation, SCOPE reports integer-valued copy numbers and allows 312 direct ploidy estimation, which is calculated as the weighted average of the estimated 313 copy number across the genome. For further downstream analysis, SCOPE also includes 314 the option to cluster cells based on the matrix of normalized -scores, estimated copy 315 numbers, or estimated changepoints, which returns clusters of cells from the same 316 subclones with the same mutational profiles. As a final step, cells from the same subclone 317 can be combined together to generate pseudo-bulk samples that are presumably 318 homogeneous. Another normalization on the in silico generated pseudo-bulk samples 319 Supplementary Table S1 . 332
333
Results 334
We first set out to compare the biases and differences in depth of coverage and coverage 335 uniformity between the conventional whole-genome amplification methods and the 10X 336
Genomics pipeline. Compared to protocols that use conventional methods for cell 337 isolation and whole-genome amplification (WGA), 10X Genomics produces data with both 338 higher throughput (by the number of cells captured and sequenced) and yet significantly 339 lower sequencing depth ( Supplementary Table S1 ). Conventional WGA data achieves a 340 mean total read count of 5.3 million per cell, while 10X Genomics data achieves a mean 341 total read count of 0.4 million per cell (Supplementary Figure S5A) . To assess coverage 342 uniformity, we compared the cell-specific median absolute deviation (MAD) of all pairwise 343 differences in read counts between neighboring bins, with a default bin size of 500kb for 344 all platforms and datasets (refer to the Discussion section on choice of bin size). We pre-345 normalized the read count data by a cell-specific factor for library size difference and a 346 bin-specific factor for baseline coverage difference, then calculated the MADs across all 347 cells; the MADs are resilient to outliers, as the transitions between copy number states 348 are relatively infrequent along the genome. Strikingly, our results show that, even though 349 cells from the 10X Genomics pipeline are sequenced at a much shallower depth, the 350 and the conventional methods, except that the former has a higher number of cell outliers 352 (Supplementary Figure S5B) . 353
354
Analysis of scDNA-seq data of breast cancer patients with aCGH for validation 355
We first demonstrated SCOPE on the scDNA-seq data of two breast cancer patients, T10 tumor. 22 We sought to apply SCOPE to this dataset to replicate previous findings, and, 367 further, used copy number calls by aCGH as orthogonal validations. 368 Figure 4 gives heatmaps of genome-wide estimated copy numbers across all cells 369 from T10 and T16. SCOPE identified two subpopulations of hyperdiploid cancer cells, 370 one subpopulation of hypodiploid cancer cells, and a normal cell subpopulation within 371 T10, which is consistent with the previous report. For T16, SCOPE returned two cancer 372 cell subclones, one for the hyperdiploid subpopulation from the primary tumor and the 373 other for the hyperdiploid subpopulation from the metastasis. Upon careful inspection of 374 the consensus copy number profiles of these two subpopulations, we find them highly 375 similar, indicating that the same subclone of origin from the primary tumor survived the 376 selection bottleneck and led to relapse. Notably, SCOPE also identified three 377 pseudodiploid cells (red annotation bars in Figure 4B ), in concordance with the previous 378 report. Overall, we showed that SCOPE was able to reproduce subclonal structures that 379 are consistent with previous results. The normalization results by SCOPE attain better 380 separation of signal from noise than other existing methods, as can be seen from the 381 (for T10 and T16, respectively). If we only focus on normal cells, there is an even clearer 383 separation of normalized copy numbers, as shown by the disappearance of the spike at 384 two from the normal cells (Supplementary Figure S7 ). In addition, the ploidy estimates by 385 SCOPE are highly concordant with those from previous reports based on single-cell flow 386 sorting (Supplementary Figure S8) . 387
To further assess the performance of SCOPE and to benchmark against existing 388 methods, we adopted CNV calls from aCGH of purified bulk samples 42 as gold standards 389
( Supplementary Table S3 ). FACS revealed three cancer subpopulations (aneuploid 1, 390 aneuploid 2, and hypodiploid), which is, again, in concordance with SCOPE's results. This 391 was followed by aCGH for copy number profiling of the purified bulk samples. Relative 392 copy numbers from aCGH, scDNA-seq by SCOPE, and scDNA-seq by Ginkgo are shown 393
in Figure 5A -C across the three cancer subpopulations: for aCGH, the subpopulations 394 were inferred by the initial step of flow sorting; for SCOPE and Ginkgo, the subpopulations 395 were inferred and aggregated based on the estimated single-cell copy number profiles. 396
Notably, array-based intensity measurements were normalized against a sample-specific 397 baseline, producing copy number signals that have a mean of one for all three 398 subpopulations. Therefore, relative copy numbers, which are absolute copy numbers 399 adjusted by ploidy (shown as horizontal solid lines in Figure 5A -C for diploid regions) were 400 used by Ginkgo and SCOPE to mask ploidy for comparison against aCGH calls. Using 401 spearman correlation and root mean squared error (RMSE) as performance metrics, 402 SCOPE outperforms Ginkgo by the aCGH gold standards. 403 404
Analysis of scDNA-seq data of triple-negative breast cancer patients with paired 405
WES and scRNA-seq 406
We further applied SCOPE to scDNA-seq data of temporally separated tumor resections 407 from triple negative breast cancer patients with chemotherapy treatment. 24 Specifically, 408 scDNA-seq was performed on matched pre-treatment, mid-treatment, and post-treatment 409 tumor samples from the same patient. We applied SCOPE to four "clonal extinction" 410 patients, where tumor cells were previously reported to exist only in the pre-treatment 411 samples ( Supplementary Table S1 ). For example, 92 cells from patient KTN302 were 412 detected two subclones of aneuploid cells in the pre-treatment tumors and found that all 414 the cells from the mid-treatment group were normal, as shown in Figure 6 . The consensus 415 copy number profiles of the two subpopulations indicate a large number of shared CNAs 416 between the two inferred subclones; this is, likely due to a punctuated copy number 417 evolution, 43 which produces the majority of CNAs in the early stages of tumor evolution. 418
Results for patients KTN126 and KTN129 are included in Supplementary Figure S10 . 419
We used bulk-tissue WES and single-cell RNA-seq data to validate the copy 420 number profiles returned by SCOPE. For the data from patient KTN302, WES and 421 scRNA-seq were performed on the matched normal (blood), pre-treatment, mid-treatment, 422
and post-treatment bulk samples ( Supplementary Table S1 ) and were used to profile 423
CNAs separately for validation. For bulk WES, a modified CBS algorithm based on 424 seqCBS 35 was utilized for the paired tumor-normal experimental design, which returns 425 relative copy numbers. Despite signal attenuation due to intra-tumor heterogeneity and 426 normal cell contamination, we observe large deletions on chromosome 5, 10, and 18, and 427 a distinct copy-number amplification on chromosome 8, in accordance with the profiles 428 returned by scDNA-seq ( Figure 6, Supplementary Figure S10 ). For scRNA-seq, we used 429 the InferCNV toolkit 44 and employed a sliding-window approach of 50 genes 45 to infer 430
CNVs, using as input the transcript per million (TPM) matrix, returned by SALMON 431 (Supplementary Figure S9) . 46 In spite of the low resolution, we observed deletions on 432 chromosome 5, 10, and 18, as well as duplications on chromosome 8, in accordance with 433 WES and scDNA-seq calls (Figure 6, Supplementary Figure S10) . 434
To quantitatively assay the quality of the call set produced by SCOPE, we plotted 435 the relative copy number estimates by WES and scDNA-seq for the inferred amplified, 436 deleted, and copy-number-neutral regions by SCOPE. Although the copy number signals 437 from WES and scRNA-seq are low-resolution and are attenuated due to normal cell 438 contaminations, the relative copy numbers from both WES and scRNA-seq are less than 439 one for deletion regions, but greater than one for putative amplifications, in agreement 440 with results from SCOPE (Figure 7, Supplementary Figure S11) . Notably, in the WES and 441 scRNA-seq data, the relative copy numbers in the null regions are less than one due to 442 over-normalization of ploidy in hyperdiploid samples (Figure 7, Supplementary Figure  443 S11). 444 445
Analysis of scDNA-seq data of gastric cancer spike-ins and breast cancer 446 dissections from the 10X Genomics 447
We finally demonstrated SCOPE on three recently released scDNA-seq datasets from 448 the 10X Genomics Single-Cell CNV Solution pipeline. We first adopted two publicly 449 available spike-in datasets from the 10X Genomics website, where 1% and 10% MKN-45 450 gastric cancer cell lines are mixed with ~500 and ~1000 normal BJ fibroblast cells, 451 respectively ( Supplementary Table S1 ). The second dataset consists of ~10,000 nuclei 452 extracted and sequenced from five different dissections of frozen breast tumor tissue from 453 a triple negative ductal carcinoma ( Supplementary Table S1 ). 454
As a proof of concept, we started by applying SCOPE to the two 10X Genomics 455 spike-in datasets-1,055 single cells with a 1% spike-in of cancer cells and 462 single 456 cells with a 10% spike-in of cancer cells were sequenced. We adopted stringent quality 457 control procedures to remove cells with extreme Gini coefficients and to remove bins that: 458 (i) have low mappability; (ii) reside in "blacklist" regions; and (iii) have extremely low read 459 depth across cells. For the two spike-in datasets, this resulted in 5,055 and 5,064 bins for 460 the copy number estimation, respectively. Despite the higher sparsity and lower 461 sequencing depth of this data, SCOPE successfully identified the cancer cell cluster from 462 the cluster of normal diploid cells, with heatmaps shown in Supplementary Figure S12 . 463
Specifically, 11 and 36 cancer cells were identified from the 1% and 10% spike-in datasets 464 respectively, with estimated proportions as 1% and 8%. For data visualization, we 465 performed t-SNE projections 47 on the normalized -scores, revealing that SCOPE 466 successfully recovers 1% and 10% non-diploid cancer cells from a mixture of diploid cells 467 in the background (Figure 8A-B) . The colors in Figure 8A -B indicate the classification by 468 a threshold of 0.12 for the Gini coefficients. We see that while not all diploid cells are used 469 as negative control cells, there is a perfect separation between normal cells and cancer 470 cells; see under Discussion for details on setting the threshold of Gini coefficients. 471
We further applied SCOPE to a 10X Genomics scDNA-seq dataset of ~10,000 472 cells from five adjacent tumor dissections of a breast cancer patient. We followed the 473 same quality control procedure as previously described, which resulted in 4864, 5016, 474 5032, 5023, and 5026 bins from each dissection. SCOPE is then separately applied to 475 each dissection for identification of normal cells, read depth normalization, and copy 476 number estimation. The proportions of normal cells vary across the five dissections, with 477 mean cellular ploidy of sections A to E being 2.12, 3.13, 3.29, 3.36, and 3.53, respectively. 478
This indicates a gradient of normal cells contaminating the tumor (Supplementary Figure  479   S13 ). We further integrated the inferred copy number profiles by SCOPE across all tumor 480 cells from the five dissections and demonstrated that SCOPE was able to identify 481 subclonal structures. For example, the distinct duplication events on chromosome 3 and 482 chromosome 4 are mutually exclusive and mark a split in the tumor evolutionary history. 483
Hierarchical clustering based on the normalization result suggests that the different 484 cancer subclones consist of cancer cells from all sections. This indicates an early 485 branching evolutionary model, where copy number aberrations happen at a potentially 486 early stage in the disease advancement ( Figure 8C) . 487 488
Discussion 489
Here we propose SCOPE, a new method to remove technical noise and improve CNV 490 signal-to-noise ratio for scDNA-seq data. SCOPE includes a Poisson latent factor model 491 for data normalization and a non-parametric functional term for adjusting GC content bias 492 in a context-specific manner. The EM algorithm embedded in the Poisson log linear model 493 accounts for the different copy number states as it adjusts for GC content bias-a step 494 we show to be crucial for cancer genomic studies, where recurrent copy number changes 495 across the genome lead to significant deviations from the null. Capacity is increasing in 496 single-cell isolation and single-cell whole-genome sequencing, and there is an increasing 497 need to profile CNVs at the single-cell level as a non-negligible source of genetic variation. 498
We believe that SCOPE can be a useful tool for the genetics and genomics community, 499
for it lays the statistical foundation that will make robust and accurate single-cell CNV 500 profiling possible. 501
We demonstrated SCOPE on two breast cancer scDNA-seq datasets, where 502 SCOPE successfully parsed normal cells, exposed a mixture of tumor cells based on their 503 inferred copy number profiles, and unmasked the ploidy. We showed that this enabled 504 characterization of genetically distinct populations of tumor cells that were not evident in 505 bulk-tissue analysis, shedding light upon tumor heterogeneity at a much finer resolution. 506
We benchmarked SCOPE against other existing methods using array-based CNV calls 507 from purified bulk samples as the gold standard, and we showed that SCOPE 508 outperformed those methods. We further demonstrated SCOPE on scDNA-seq data from 509 the recently released Single Cell CNV Solution by 10X Genomics and showed that 510 SCOPE could accurately detect 1% of the gastric cancer cells from the background of 511 normal fibroblast cells and that it successfully reconstructed the subclonal structure 512 across 10,000 breast cancer cells. 513
To systematically investigate how varying parameters (e.g., bin size, threshold of 514 cell-specific Gini coefficients to identify normal controls, and the number of Poisson latent 515 factors) influence performance, we carry out additional evaluation and benchmark 516 analysis on the scDNA-seq data from the breast cancer patient T10, with the aCGH calls 517 as gold standard. Our results indicate that a bin size of 3Mb, compared to a bin size of 518
200Kb, leads to smoother normalization results yet meanwhile misses smaller CNVs due 519 to low resolution (Supplementary Figure S14) . Meanwhile, bin sizes between 200Kb to 520 1Mb do not affect the performance of SCOPE, especially for chromosome-arm level 521 Figure S15) . For an optimal choice of the Gini coefficient threshold, 522
CNVs (Supplementary
we provided empirical evidence that SCOPE does not need to include all normal cells as 523 negative controls -10 to 20 normal cells suffice to achieve accurate estimation 524 (Supplementary Figure S16 ). In addition, we show that SCOPE's performance is invariant 525 to the choice of , the number of Poisson latent factors (Supplementary Figure S17) , 526 since SCOPE adopts the EM algorithm to account for genomic contexts when estimating 527 GC content biases and uses only the normal cells to estimate the bin-specific noise terms. 528
As such, we show that SCOPE is robust to the choice of Gini coefficient threshold and 529 the number of Poisson latent factors. In summary, compared to existing methods, SCOPE 530 directly provides copy number and ploidy estimates, completely off the shelf and without 531 much need for manual tuning by the users. 532
Correct inference of tumor evolution history depends on accurate copy number 533 estimates, which in turn depend on effective normalization. While we show that data 534 normalization is a first-order concern, the cross-sample segmentation procedure by 535 necessary for the single-cell setting, where cells from the same genetic backgrounds 537 share the same breakpoints. SCOPE also enables hierarchical clustering and phylogeny 538 reconstruction, based on the normalized log-ratios, the estimated copy numbers, or the 539 estimated changepoints-data that is useful for further downstream analysis. To further 540 reduce the ambiguity in unmasking intra-tumor heterogeneity, future research may 541 include force-calling somatic point mutations from scDNA-seq and integrating both copy 542 number and point mutation profiles for reconstructing tumor evolutionary history. Each genomic segment is categorized as amplification (amp), deletion (del), or copy-746 number neural (null) based on the copy number estimates returned by SCOPE. The 747 boxplot shows the estimated relative copy numbers by bulk WES and scRNA-seq, which 748 are higher in amplified regions and lower in deleted regions, compared to the null regions. 749
Due to low resolution and high signal-to-noise ratio by WES and scRNA-seq, there is no 750 perfect separation between the different copy number states. Furthermore, for scRNA-751 seq and bulk WES, the relative copy numbers are estimated comparing to a sample-752 specific baseline. For cases where the tumor cells are hyperdiploid/hypodiploid, the 753 baseline is shifted up/down making the true null regions have relative copy numbers 754 less/greater than one. 755 756 
SCOPE normalization
Estimated copy number Gini<=0.12 Gini>0.12
